Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up.
about
Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic reviewGlatiramer acetate for multiple sclerosisDisease modifying agents for multiple sclerosis.Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies.Glatiramer acetate for the treatment of multiple sclerosis.Spasticity in multiple sclerosis and role of glatiramer acetate treatment.Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala studyTolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months.Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.Update on the treatment options for multiple sclerosis.Adaptive immune responses in CNS autoimmune disease: mechanisms and therapeutic opportunities.Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey.Influence of treatment in multiple sclerosis disability: an open, retrospective, non-randomized long-term analysis.Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta1a or glatiramer acetate compared with untreated patients.Managing loss of intrathecal baclofen efficacy: Review of the literature and proposed troubleshooting algorithm.
P2860
Q22241795-9822200A-8E1A-412D-B308-098C3002D619Q24235498-0963670F-FEA3-46FD-832C-20F803CB6C43Q34508451-84C202C1-F4FB-43C7-A2A7-E7121465B5AAQ35094706-50A896FA-FD85-4AFF-BAA2-0807A9E9407FQ35753417-61C3C30A-472C-468F-A957-558D2534370DQ36109866-84645551-5BC8-478C-877C-EE39DD201F64Q36171531-A87062DF-8101-4EC8-A7A3-888C174D47E7Q36301172-7334F84B-E8BA-4F01-9A40-78A639F06EF4Q37519608-1A23A38F-B82E-4512-91A0-86CFD3ADE7F2Q37729045-EDF8942B-295B-402B-95F9-085957EADACEQ38097385-989EB43D-EF44-494D-AF9E-D01F820663C4Q42687809-B46CA18F-345B-4A5E-8A7D-6EC6AEB26F3AQ42929708-23691AB8-E303-4D3D-A998-3F894241B9C3Q44634806-0F0BEAFD-DBD0-4AAC-BEEB-600F2A25DD42Q49962049-63E8C018-E1DF-40A7-B0B1-1F8852336EB5
P2860
Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Comparison of glatiramer aceta ...... n open-label 2-year follow-up.
@en
Comparison of glatiramer acetate
@nl
type
label
Comparison of glatiramer aceta ...... n open-label 2-year follow-up.
@en
Comparison of glatiramer acetate
@nl
prefLabel
Comparison of glatiramer aceta ...... n open-label 2-year follow-up.
@en
Comparison of glatiramer acetate
@nl
P2093
P1476
Comparison of glatiramer aceta ...... n open-label 2-year follow-up.
@en
P2093
P356
10.1016/S0022-510X(02)00047-3
P577
2002-05-01T00:00:00Z